← All trials
NCT06436274
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2024
- Primary completion
- Apr 30, 2026
- Completion date
- Jun 30, 2027
- First posted
- May 31, 2024
- Last posted
- May 31, 2024
- Enrollment
- 750
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversitySponsor investigator
- Botswana Harvard Aids InstituteCollaborator
- University of the WitwatersrandCollaborator
- Government of RwandaCollaborator
- Harvard UniversityOfficial
- University of WashingtonCollaborator
- National Cancer Institute (NCI)Collaborator
- Karolinska InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.